Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYCC NASDAQ:INKT NASDAQ:PDSB NASDAQ:TIL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCCCyclacel Pharmaceuticals$6.37$7.23$0.22▼$19.87$14.26M0.153.54 million shsN/AINKTMiNK Therapeutics$12.53+4.2%$11.56$6.80▼$76.00$62.42M0.47179,394 shs27,530 shsPDSBPDS Biotechnology$1.02-2.9%$1.10$0.51▼$1.85$56.94M1.57842,839 shs1.14 million shsTILInstil Bio$7.95+0.4%$8.18$5.67▼$35.00$53.90M1.9175,790 shs28,473 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCCCyclacel Pharmaceuticals0.00%0.00%0.00%0.00%+2.97%INKTMiNK Therapeutics0.00%+1.26%+12.13%+31.80%+64.43%PDSBPDS Biotechnology0.00%+2.94%-21.64%+65.96%-40.00%TILInstil Bio0.00%-1.86%-1.86%-3.53%-76.86%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCCCyclacel Pharmaceuticals$6.37$7.23$0.22▼$19.87$14.26M0.153.54 million shsN/AINKTMiNK Therapeutics$12.53+4.2%$11.56$6.80▼$76.00$62.42M0.47179,394 shs27,530 shsPDSBPDS Biotechnology$1.02-2.9%$1.10$0.51▼$1.85$56.94M1.57842,839 shs1.14 million shsTILInstil Bio$7.95+0.4%$8.18$5.67▼$35.00$53.90M1.9175,790 shs28,473 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCCCyclacel Pharmaceuticals0.00%0.00%0.00%0.00%+2.97%INKTMiNK Therapeutics0.00%+1.26%+12.13%+31.80%+64.43%PDSBPDS Biotechnology0.00%+2.94%-21.64%+65.96%-40.00%TILInstil Bio0.00%-1.86%-1.86%-3.53%-76.86%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYCCCyclacel Pharmaceuticals 0.00N/AN/AN/AINKTMiNK Therapeutics 2.40Hold$35.00178.55% UpsidePDSBPDS Biotechnology 2.33Hold$9.00785.83% UpsideTILInstil Bio 1.67Reduce$66.00737.56% UpsideCurrent Analyst Ratings BreakdownLatest CYCC, INKT, PDSB, and TIL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2026INKTMiNK Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/18/2026INKTMiNK Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.005/12/2026INKTMiNK Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/24/2026INKTMiNK Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026PDSBPDS Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/15/2026PDSBPDS Biotechnology HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.004/1/2026INKTMiNK Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.003/27/2026TILInstil Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYCCCyclacel Pharmaceuticals$40K356.44N/AN/A($58.87) per share-0.11INKTMiNK TherapeuticsN/AN/AN/AN/A($3.03) per shareN/APDSBPDS BiotechnologyN/AN/AN/AN/A$0.18 per shareN/ATILInstil BioN/AN/AN/AN/A$16.79 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYCCCyclacel Pharmaceuticals-$11.21M-$839.58N/AN/AN/AN/A-723.64%-145.51%N/AINKTMiNK Therapeutics-$12.49M-$2.84N/AN/AN/AN/AN/A-118.57%8/13/2026 (Estimated)PDSBPDS Biotechnology-$34.50M-$0.67N/AN/AN/AN/A-346.02%-102.36%8/12/2026 (Estimated)TILInstil Bio-$71.37M-$7.08N/AN/AN/AN/A-39.76%-22.38%8/12/2026 (Estimated)Latest CYCC, INKT, PDSB, and TIL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026INKTMiNK Therapeutics-$0.77-$0.57+$0.20-$0.57N/AN/A5/15/2026Q1 2026TILInstil Bio-$0.62-$0.62N/A-$0.62N/AN/A5/13/2026Q1 2026PDSBPDS Biotechnology-$0.15-$0.13+$0.02-$0.13N/AN/A3/30/2026Q4 2025PDSBPDS Biotechnology-$0.20-$0.14+$0.06-$0.14N/AN/A3/27/2026Q4 2025TILInstil Bio-$2.31-$1.21+$1.10-$1.21$1.90 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCYCCCyclacel PharmaceuticalsN/AN/AN/AN/AN/AINKTMiNK TherapeuticsN/AN/AN/AN/AN/APDSBPDS BiotechnologyN/AN/AN/AN/AN/ATILInstil BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYCCCyclacel PharmaceuticalsN/A5.775.77INKTMiNK TherapeuticsN/A1.381.38PDSBPDS Biotechnology2.732.262.26TILInstil Bio0.7739.8739.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYCCCyclacel Pharmaceuticals23.58%INKTMiNK Therapeutics2.87%PDSBPDS Biotechnology26.84%TILInstil Bio60.56%Insider OwnershipCompanyInsider OwnershipCYCCCyclacel Pharmaceuticals51.20%INKTMiNK Therapeutics22.48%PDSBPDS Biotechnology9.20%TILInstil Bio47.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYCCCyclacel Pharmaceuticals142.24 million1.09 millionOptionableINKTMiNK Therapeutics304.98 million3.97 millionNo DataPDSBPDS Biotechnology2055.82 million50.68 millionOptionableTILInstil Bio4106.78 million3.59 millionNo DataCYCC, INKT, PDSB, and TIL HeadlinesRecent News About These CompaniesInstil Bio Shareholders Back Directors and Auditor at MeetingJune 11, 2026 | tipranks.comInstil Bio Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 15, 2026 | globenewswire.comInstil Bio (TIL) Price Target Increased by 24.53% to 67.32April 9, 2026 | msn.comInstil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateMarch 27, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILFebruary 12, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILFebruary 3, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 29, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio,January 27, 2026 | bakersfield.comBINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 27, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 22, 2026 | prnewswire.comTIL ALERT: Ongoing Investigation Into Instil Bio, Inc. - Contact Levi & KorsinskyJanuary 20, 2026 | newsfilecorp.comNINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 20, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 15, 2026 | prnewswire.comInstil Bio (TIL) Price Target Decreased by 45.17% to 53.55January 14, 2026 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 13, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 8, 2026 | prnewswire.comHC Wainwright & Co. downgrades Instil Bio (TIL)January 8, 2026 | msn.comArrowhead showcases early obesity data; Instil bails on PD-1/VEGF drugJanuary 7, 2026 | biopharmadive.comBInstil Bio shares slide on discontinuation of lead clinical programsJanuary 6, 2026 | proactiveinvestors.comInstil Bio Pulls Plug On Lead Drug DevelopmentJanuary 6, 2026 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYCC, INKT, PDSB, and TIL Company DescriptionsCyclacel Pharmaceuticals NASDAQ:CYCCCyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.MiNK Therapeutics NASDAQ:INKT$12.53 +0.51 (+4.24%) Closing price 04:00 PM EasternExtended Trading$12.60 +0.07 (+0.56%) As of 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.PDS Biotechnology NASDAQ:PDSB$1.02 -0.03 (-2.86%) Closing price 04:00 PM EasternExtended Trading$1.02 +0.00 (+0.49%) As of 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.Instil Bio NASDAQ:TIL$7.95 +0.03 (+0.38%) Closing price 04:00 PM EasternExtended Trading$7.92 -0.03 (-0.38%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas What's Behind the Social Media Controversy Surrounding IonQ? Mission Control: Floating In SpaceX's Record-Breaking Orbit 3 Dividend Increases Investors Can Actually Trust RH’s Strong Q1 Still Leaves Investors With One Big Question SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
